Anthropic quietly sets up biology lab as it ramps AI drug programme
AI generated
SAN FRANCISCO – Anthropic has quietly set up a laboratory to do physical biology work as it pushes its artificial-intelligence ambitions into the world of drug science.
asserted
it → set → science
At a time when fears of AI are gripping the public, the start-up has built a wet lab, or place for physical experiments, in the San Francisco Bay Area, two people familiar with the matter said.
asserted
people → grip → matter
Anthropic has said it wants to unlock treatments for rare diseases, and its biology work has gone beyond “in silico” or computer evaluations.
asserted
work → say → evaluations
In a Reuters interview on Sept 15, Anthropic’s head of life sciences, Eric Kauderer-Abrams, confirmed the start-up’s wet lab.
asserted
head → confirm → lab
“We believe that to do biology, the final test is still and will be for a while in real lab work,” he said.
asserted
he → believe → work
“We absolutely are doing that today, and I would describe our approach as being typical of what you would see in most biotech companies, where there’s some amount of that that we’re doing in our own facilities and some amount of that that we’re working with external partners on.
asserted
we → do → partners
A spokesperson later clarified that Anthropic’s lab is not for drug discovery specifically, declining to elaborate.
The move represents a small step toward Anthropic’s enormous ambition to tackle diseases that it thinks the pharmaceutical industry is neglecting – and to do so before staff and the public lose faith that AI justifies erasing jobs and possibly human life, one of the people said.
uncertain
one → clarify → people
The success of any drug programme it runs is not certain; most drugs fail to pass trials for clinical safety and efficacy.
asserted
drugs → run → safety
A disease killed his father only a few years before a cure came about, he said in a recent essay.
asserted
he → kill → essay
Kauderer-Abrams echoed the sentiment.
asserted
Abrams → echo → sentiment
“The mission of the company is to develop powerful AI in such a way that benefits the world,” Kauderer-Abrams said.
asserted
Abrams → develop → world
“By far, we see the biggest opportunity for that in the life sciences, and that is motivating everything that we’re doing.
asserted
we → see → that
Balancing ambition with fears of catastrophe
Like other biotech companies, Anthropic is embracing physical automation, said the two people, who spoke on condition of anonymity.
asserted
who → balance → anonymity
The start-up wants to push how its Claude AI can direct robotic units to carry out science experiments with limited human intervention, one of the people said.
asserted
one → want → people
Still, Anthropic believes that human oversight and involvement are essential for safety, its spokesperson said.
asserted
spokesperson → believe → safety
“We’re in the very early innings of using AI to automate the execution of lab work,” said Kauderer-Abrams, “an area that has the potential to bring about meaningful acceleration in so many different processes.
asserted
that → ’re → processes
Anthropic’s race to apply rapidly evolving technology to a biology lab comes at an extraordinary time for the company.
asserted
race → apply → company
In the past two weeks, some of its researchers warned that AI could lead to human extinction, and Anthropic said it found examples where its systems could have been used towards biological weapons development, which met some scepticism.
uncertain
which → warn → scepticism
Amodei also called for a development slowdown, saying that a future AI more capable than the OpenAI agents that hacked Hugging Face could cause catastrophic damage.
uncertain
that → call → damage
At the same time, Anthropic is preparing to go public in a potentially US$2 trillion (S$2.56 trillion) IPO to raise more money for such AI development.
asserted
Anthropic → prepare → development
“In our life-science work, we’re always balancing these things,” Kauderer-Abrams said, “making models better in ways that we think will uplift and accelerate developing medicines, and being thoughtful and careful about how we deploy it to limit the risk.”
asserted
we → balance → risk
Procurement ramp-up
Anthropic staked out its intention to start running drug programmes, at a San Francisco event in June.
asserted
Anthropic → stake → June
On stage there, Kauderer-Abrams said Anthropic would do pre-clinical work in areas that traditional companies did not find attractive financially.
asserted
companies → say → areas
The company also launched software called Claude Science, and it earlier added Novartis CEO Vas Narasimhan to its board and bought the start-up Coefficient Bio for about US$400 million in stock, according to media reports.
uncertain
it → launch → reports
Anthropic confirmed the acquisition, which will help it build tools for drug development, but it had no comment on the deal price.
asserted
it → confirm → price
Now, Anthropic is bulking up its in-house lab efforts for speed and for first-hand experience in biology, though it outsources work when efficient, Kauderer-Abrams told Reuters.
asserted
Abrams → bulk → Reuters
“There’s some things that we can do much faster in our own hands,” he said, with the goal “to operate at the largest possible scale”.
asserted
he → ’ → scale
Anthropic has looked to hire a leader who could ramp up procurement and other operations, it said in a recent LinkedIn job post.
uncertain
it → look → post
Another Anthropic role solicited via Jobera sought an expert on “protein and nucleic acid characterisation,” among other biochemical work.
asserted
role → solicit → work
A third Anthropic job listing read: “Our goal is to speed up progress in the life sciences by an order of magnitude.”
asserted
goal → read → magnitude
Life sciences already represents one of Anthropic’s biggest investment areas by headcount and resources, Kauderer-Abrams said.
asserted
Abrams → represent → headcount
Targeting ‘undruggable’ conditions
asserted
Targeting → target → conditions
His view is that AI could fast-track development for conditions previously thought to be “undruggable” – too difficult to treat.
uncertain
AI → track → conditions
The technology could speed up discovery, for instance, of bispecific and trispecific antibodies, complex molecules that can be directed at multiple points on a targeted protein or cell, or hit multiple targets.
uncertain
that → speed → targets
The precise diseases Anthropic is addressing and its progress remain unclear.
uncertain
Anthropic → address → ?
Once a molecule is identified, it can take years to bring a drug to market as it is tested in human trials, a challenge that Anthropic has not taken on.
asserted
Anthropic → identify → that
Isomorphic Labs, the drug discovery arm of rival Alphabet, has worked for years to get to the clinic and earlier delayed that goal to the end of 2026.
asserted
Labs → work → 2026
In its efforts at lab and other industry automation, Anthropic launched the Model Hardware Standard in August, which helps AI operate equipment.
asserted
AI → launch → equipment
A release out of academia called PyLabRobot, unrelated to Anthropic, earlier addressed related though different automation needs.
asserted
release → call → needs
Anthropic is providing work like the Model Hardware Standard and broader AI services and tools to all manner of top pharmaceutical companies, such as Roche’s Genentech, Bristol Myers Squibb and Novo Nordisk.
asserted
Anthropic → provide → Genentech
…and 4 more, not listed.
The Aporia
